As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Hepatocellular Cancer Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 125 high prescribing medical oncologists and hepatologists, and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Medical Oncologists 30 0 31 30 30 30 30
Hepatologists 0 30 0 0 0 0 0

Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2013-2022
Patient subpopulations forecasted
  • Resectable
  • Unresectable
Drugs profiled
  • ADI-PEG 20
  • Muparfostat
  • Nexavar
  • Orantinib
  • Peretinoin
  • Stivarga
  • Ramucirumab

Key Findings

The combined value of hepatocellular cancer (HCC) drugs in the US, Japan, and five major EU markets will peak at $1.4bn in 2019. The strong forecasted growth over 2013–19 is attributable to generation of revenue derived from new HCC patient populations. Datamonitor Healthcare expects that Nexavar uptake will increase as it will gain approval for adjuvant treatment of early-stage resectable HCC. In addition, a wave of new drugs will be indicated for second-line treatment of unresectable advanced or metastatic HCC. High unmet need in this patient population will drive uptake of these therapies.


> Download your free sample > Contact us to find out more



Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726